<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CURRENT REPORT FOR ISSUERS SUBJECT TO THE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">1934 ACT REPORTING REQUIREMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Washington, DC 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CURRENT REPORT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Pursuant to Section 13 or 15(d) of the Securities
Exchange Act</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report&nbsp;&nbsp;(Date of Earliest
Event Reported): July 13, 2012</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Radient Pharmaceuticals Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; text-align: center">Delaware</TD>
    <TD STYLE="width: 34%; text-align: center">001-16695</TD>
    <TD STYLE="width: 33%; text-align: center">33-0413161</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">(State&nbsp;or&nbsp;other</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">jurisdiction&nbsp;of</TD>
    <TD STYLE="text-align: center">(Commission&nbsp;File&nbsp;Number)</TD>
    <TD STYLE="text-align: center">(IRS&nbsp;Employer&nbsp;Identification&nbsp;No.)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">incorporation)</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2492 Walnut Avenue, Suite 100, Tustin, California,
92780-7039</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices
(zip code))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">714-505-4461</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&rsquo;s telephone number, including
area code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2 below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Wingdings">&#168;</FONT> Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Wingdings">&#168;</FONT> Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a - 12)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Wingdings">&#168;</FONT> Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Wingdings">&#168;</FONT> Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13d-4(c))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section 1 &ndash; Registrant&rsquo;s Business
and Operations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 1.01 &ndash; Entry into Material
Definitive Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">On July 13, 2012, we
entered into a license agreement with Global Cancer Diagnostics, Inc. (&quot;GCDx&quot;) in order to commercialize certain of our
intellectual property in the form of a Lung Cancer test; the intellectual property at issue is specified in the Agreement and is
herein referred to as the Licensed Products. Under the Agreement, GCDx will be the only company offering a test specific to lung
cancer but will not make, use of or sell any of our other tests using the DR-70 reagents. GCDx will pay an upfront license fee
of $200,000 for the Licensed Products and will pay for all costs related to patent and FDA filings for the Licensed Products. Both
parties recognize the need for additional development and testing of the Licensed Products to obtain FDA Approval of same. The
parties shall meet on a quarterly basis to discuss the Licensed Products and the best ways to ensure protection of same. GCDx shall
pay us royalties, which shall be earned only upon actual receipt of payment of revenue or sublicense license fees and sublicense
royalty fees by GCDx, as set forth in the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Although GCDx will pay
all costs related to developing the Licensed Products for commercial applications, including process development costs, clinical
study costs and costs related to the FDA filing and approval process, the parties agreed that GCDx shall pay us $150 per hour for
any additional services GCDx requests above those services initially contemplated to carry out this development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The Agreement contains
non-compete and confidentiality terms regarding the Licensed Products, the latter of which expires 5 years after the Agreement
terminates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The Agreement shall be
in effect until the earlier to occur of: (i) expiration of the last patent issued to us for the Licensed Products, (ii) when GCDx
terminates the Agreement by discontinuing the offering of the Licensed Products or the sublicense to do the same, as such discontinuance
is defined in the Agreement, for a full calendar year - at which time the license rights will by default return to us, or (iii)
by us, if GCDx does not achieve sales necessary to meet the contractually agreed to Minimum Royalty Payments, as such term is defined
in the Agreement, for any two consecutive fiscal quarters. Additionally, either party may terminate the Agreement upon 30 days
written notice to the other party. The terms of the Agreement provide that if either party terminates the Agreement or the Agreement
expires due to nonpayment or otherwise, any and all license rights will revert back to us. Three months after the date of reversion,
we will be entitled to enter new contractual agreements with third parties with regard to such rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing document and transaction
descriptions above are&nbsp;&nbsp;not complete and are subject to and qualified in their entirety by reference to the exhibits
attached hereto and incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The transaction documents have been included
to provide investors and security holders with information regarding their respective terms. They are not intended to provide any
other financial information about us or our subsidiaries and affiliates. The representations, warranties and covenants contained
in the transaction documents were made only for purposes of those agreements and as of specific dates; were solely for the benefit
of the parties to such agreements; may be subject to limitations agreed upon by the parties, including being qualified by confidential
disclosures made for the purposes of allocating contractual risk between the parties to the agreements instead of establishing
these matters as facts; and may be subject to standards of materiality applicable to the contracting parties that differ from those
applicable to investors. Investors should not rely on the representations, warranties and covenants or any description thereof
as characterizations of the actual state of facts or condition of us or our subsidiaries or affiliates. Moreover, information concerning
the subject matter of the representations, warranties and covenants may change after the date of the agreements, which subsequent
information may or may not be fully reflected in public disclosures by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to the foregoing, as we have
previously disclosed, as a result of our working capital deficiencies, we previously disclosed that we laid off a substantial portion
of our work force and are currently operating on a minimal basis with only 2 employees and three former employee consultants. The
current focus of our operations is to ensure that our existing Onko-Sure&reg; customers and any future customers are able to place
orders and receive kits on a timely basis. We have an Onko-Sure&reg; production continuity arrangement in place with one vendor.
At the current time, the Company believes that it does not require any additional staff to perform this limited manufacturing,
quality control and selling process. Furthermore, although the upfront licensing fee and potential ongoing licensing fees may help
off-set certain of our working capital deficiencies, it will not be sufficient to allow us to reestablish normal operations at
this time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 9.01 Financial Statements and Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(c) Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 13%; font-weight: bold; text-align: justify">Exhibit&nbsp;No.</TD>
    <TD STYLE="width: 87%; font-weight: bold; text-align: justify">Description</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">10.1</TD>
    <TD STYLE="text-align: justify">Agreement with Global Cancer Diagnostics, Inc. dated July 13, 2012</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 56%"><TR STYLE="vertical-align: top"><TD COLSPAN="2"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>RADIENT<BR>
PHARMACEUTICALS CORPORATION</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 56%">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 50%; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">By:</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: justify">/s/ Douglas C. MacLellan</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Name:&nbsp;&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">Douglas C. MacLellan&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Title:&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">Chairman &amp; CEO</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dated: July 17, 2012&nbsp;</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "v318772_8k.htm", "description": "FORM 8-K", "secsgml_size_bytes": 19493}]
{"company-data": {"conformed-name": "RADIENT PHARMACEUTICALS Corp", "cik": "0000838879", "assigned-sic": "2834", "irs-number": "330413161", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-16695", "film-number": "12965418"}, "business-address": {"street1": "2492 WALNUT AVENUE", "street2": "STE 100", "city": "TUSTIN", "state": "CA", "zip": "92780", "phone": "7145054460"}, "mail-address": {"street1": "2492 WALNUT AVENUE", "street2": "STE 100", "city": "TUSTIN", "state": "CA", "zip": "92780"}, "former-company": [{"former-conformed-name": "AMDL INC", "date-changed": "19920703"}, {"former-conformed-name": "CALIFORNIA VENTURES INC", "date-changed": "19890905"}]}
CURRENT REPORT FOR ISSUERS SUBJECT TO THE
1934 ACT REPORTING REQUIREMENTS
FORM 8-K
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act
Date of Report  (Date of Earliest
Event Reported): July 13, 2012
Radient Pharmaceuticals Corporation
(Exact name of registrant as specified in
its charter)
Delaware
001-16695
33-0413161
(State or other
jurisdiction of
(Commission File Number)
(IRS Employer Identification No.)
incorporation)
2492 Walnut Avenue, Suite 100, Tustin, California,
92780-7039
(Address of principal executive offices
(zip code))
714-505-4461
(Registrant's telephone number, including
area code)
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2 below):
¨
Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a - 12)
¨
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13d-4(c))
Section 1 – Registrant's Business
and Operations
Item 1.01 – Entry into Material
Definitive Agreements
On July 13, 2012, we
entered into a license agreement with Global Cancer Diagnostics, Inc. ("GCDx") in order to commercialize certain of our
intellectual property in the form of a Lung Cancer test; the intellectual property at issue is specified in the Agreement and is
herein referred to as the Licensed Products. Under the Agreement, GCDx will be the only company offering a test specific to lung
cancer but will not make, use of or sell any of our other tests using the DR-70 reagents. GCDx will pay an upfront license fee
of $200,000 for the Licensed Products and will pay for all costs related to patent and FDA filings for the Licensed Products. Both
parties recognize the need for additional development and testing of the Licensed Products to obtain FDA Approval of same. The
parties shall meet on a quarterly basis to discuss the Licensed Products and the best ways to ensure protection of same. GCDx shall
pay us royalties, which shall be earned only upon actual receipt of payment of revenue or sublicense license fees and sublicense
royalty fees by GCDx, as set forth in the Agreement.
Although GCDx will pay
all costs related to developing the Licensed Products for commercial applications, including process development costs, clinical
study costs and costs related to the FDA filing and approval process, the parties agreed that GCDx shall pay us $150 per hour for
any additional services GCDx requests above those services initially contemplated to carry out this development.
The Agreement contains
non-compete and confidentiality terms regarding the Licensed Products, the latter of which expires 5 years after the Agreement
terminates.
The Agreement shall be
in effect until the earlier to occur of: (i) expiration of the last patent issued to us for the Licensed Products, (ii) when GCDx
terminates the Agreement by discontinuing the offering of the Licensed Products or the sublicense to do the same, as such discontinuance
is defined in the Agreement, for a full calendar year - at which time the license rights will by default return to us, or (iii)
by us, if GCDx does not achieve sales necessary to meet the contractually agreed to Minimum Royalty Payments, as such term is defined
in the Agreement, for any two consecutive fiscal quarters. Additionally, either party may terminate the Agreement upon 30 days
written notice to the other party. The terms of the Agreement provide that if either party terminates the Agreement or the Agreement
expires due to nonpayment or otherwise, any and all license rights will revert back to us. Three months after the date of reversion,
we will be entitled to enter new contractual agreements with third parties with regard to such rights.
The foregoing document and transaction
descriptions above are  not complete and are subject to and qualified in their entirety by reference to the exhibits
attached hereto and incorporated herein by reference.
The transaction documents have been included
to provide investors and security holders with information regarding their respective terms. They are not intended to provide any
other financial information about us or our subsidiaries and affiliates. The representations, warranties and covenants contained
in the transaction documents were made only for purposes of those agreements and as of specific dates; were solely for the benefit
of the parties to such agreements; may be subject to limitations agreed upon by the parties, including being qualified by confidential
disclosures made for the purposes of allocating contractual risk between the parties to the agreements instead of establishing
these matters as facts; and may be subject to standards of materiality applicable to the contracting parties that differ from those
applicable to investors. Investors should not rely on the representations, warranties and covenants or any description thereof
as characterizations of the actual state of facts or condition of us or our subsidiaries or affiliates. Moreover, information concerning
the subject matter of the representations, warranties and covenants may change after the date of the agreements, which subsequent
information may or may not be fully reflected in public disclosures by us.
In addition to the foregoing, as we have
previously disclosed, as a result of our working capital deficiencies, we previously disclosed that we laid off a substantial portion
of our work force and are currently operating on a minimal basis with only 2 employees and three former employee consultants. The
current focus of our operations is to ensure that our existing Onko-Sure® customers and any future customers are able to place
orders and receive kits on a timely basis. We have an Onko-Sure® production continuity arrangement in place with one vendor.
At the current time, the Company believes that it does not require any additional staff to perform this limited manufacturing,
quality control and selling process. Furthermore, although the upfront licensing fee and potential ongoing licensing fees may help
off-set certain of our working capital deficiencies, it will not be sufficient to allow us to reestablish normal operations at
this time.
Item 9.01 Financial Statements and Exhibits
(c) Exhibits
Exhibit No.
Description
10.1
Agreement with Global Cancer Diagnostics, Inc. dated July 13, 2012
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
RADIENT
PHARMACEUTICALS CORPORATION
By:
/s/ Douglas C. MacLellan
Name:
Douglas C. MacLellan
Title:
Chairman & CEO
Dated: July 17, 2012